Proprietary, Multi-Detector Materials Testing Process Supports Faster Regulatory Approvals
PITTSBURGH, Sept. 7, 2022 – RQM+, the leading MedTech service provider with the world’s largest
global team of regulatory and quality experts, and portfolio company of Linden Capital Partners, today
announced the acquisition of Jordi Labs. With these new capabilities, RQM+ provides comprehensive
regulatory, quality, clinical and laboratory services, supporting market access throughout the entire
product lifecycle for medical devices and diagnostics.
“As the only MedTech service provider rooted in almost 40 years of regulatory strategy, RQM+ is proud
to now offer proprietary testing services for extractables and leachables, which gives our customers the
fastest path to regulatory approvals,” said CEO Margaret Keegan. “We are relentlessly focused on being
the best at every service we provide to MedTech manufacturers. Jordi’s world-leading testing services
will help us maintain our uncompromising quality standards at every stage as we grow into a one-stop-
shop to expedite patient access to life-improving technologies.”
Through innovative new processes, Jordi Labs provides chemical characterization and complex product
deformulation as well as contaminant and failure investigations to MedTech manufacturers. Their team
of Ph.D. analytical chemists uses its proprietary, multi-detector approach to ensure that all extractables
are accurately characterized to comply with global materials testing regulatory requirements. Jordi’s
publications based on their multi-detector approach are frequently cited by both regulators and
“We are delighted to now be a part of the RQM+ solution that brings customers to market faster with
our unmatched track record of rapid testing results that satisfy the stringent requirements of regulators
globally,” said Mark Jordi, president of Jordi Labs. “Joining RQM+ will enable me to focus on what I love
– developing groundbreaking technology that ensures patient safety by setting new standards for
extractables and leachables testing.”
Kirkland and Ellis LLP served as legal advisor to Linden. Harris Williams represented Jordi Labs.
RQM+ is the leading MedTech service provider with the world’s largest global team of regulatory and
quality experts. We provide comprehensive regulatory, quality, clinical and laboratory services,
supporting market access throughout the entire product lifecycle for medical devices and diagnostics.
With more former FDA, MHRA and notified body regulators than any other firm, the RQM+ team has
deep expertise in all clinical specialties. RQM+ currently works for eight of the top 10 medical device
manufacturers and seven of the top 10 IVD companies. For more information, visit RQMplus.com.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on the healthcare
industry. Founded in 2004, Linden is one of the country’s largest dedicated healthcare private equity
firms. Linden’s strategy is based upon three elements: (i) healthcare specialization, (ii) integrated private
equity and operating expertise, and (iii) its differentiated human capital program. Linden invests in
middle market platforms in the medical products, specialty distribution, pharmaceutical, and services
segments of healthcare. Since its founding, Linden has invested in over 45 healthcare companies
encompassing over 250 total transactions. The firm has raised over $6.5 billion in limited partner
commitments since inception. For more information, please visit www.lindenllc.com.